Imatinib as a possible cause of severe rhabdomyolysis

New England Journal of Medicine

Volumn 358, Issue 25, 2008, Pages 2746-2747

  Penel, Nicolas ^a   Blay, Jean Yves ^b   Adenis, Antoine ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; NEUROLEPTIC AGENT; ZIDOVUDINE;

ADULT; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FIBROMATOSIS; HUMAN; HYPEREOSINOPHILIA; LETTER; MYALGIA; PRIORITY JOURNAL; PRURITUS; RASH; RHABDOMYOLYSIS;

EID: 45549090761     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0708896     Document Type: Letter

References (3)

1. Siddiqui MA, Scott LJ. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 2007;67:805-20.
2. Penel N, Bui BN, Le Cesne A, et al. Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment: a phase II trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2006;25:Suppl:18S. abstract.
3. Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med 2007;2:210-8.